Accessibility Menu
Izotropic logo

Izotropic(OTC) IZOZF

Market Cap$11.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
$0.17
+1.28%
+0.00Today

Izotropic Financials at a Glance

Market Cap

$11.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$2.52M

EPS (TTM)

-$0.03

P/E Ratio

-6.08

Dividend

$0.00

Beta (Volatility)

0.22 (Low)

Price

$0.17

Volume

4,500

Open

$0.17

Previous Close

$0.17

Daily Range

$0.17 - $0.17

52-Week Range

$0.12 - $0.37

Estimated Earnings Date

Mar 30, 2026

IZOZF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Izotropic

Izotropic Corporation is a medical technology company dedicated to advancing diagnostic solutions for breast cancer. The firm specializes in developing and selling a specialized breast CT imaging system and a 3D CT breast imaging platform, aimed at enhancing early detection and accurate diagnosis of breast cancer.

Products and Services
  • Specialized breast CT imaging system for enhanced diagnostics
  • 3D CT breast imaging platform for improved detection
  • Research and development focused on innovative medical technologies
Growth Outlook
  • Significant market potential in breast cancer diagnostics
  • Continued investment in research and development initiatives
  • Strategic partnerships to expand market reach and capabilities
Financial Highlights
  • Recent quarterly net income of -$262,522, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) revenue of $0, indicating a focus on product development
  • Cash and cash equivalents increased to $364,655 in the latest quarter
Izotropic Corporation operates in a critical sector, focusing on breast cancer diagnostics, which is increasingly important given the rising incidence of breast cancer globally. The company's innovative imaging technologies are designed to improve patient outcomes through earlier and more accurate detection. Despite reporting no revenue in recent quarters, the firm is heavily investing in research and development, which is essential for future growth and product commercialization. The increase in cash reserves indicates a potential for sustained operations and further development of its technologies. As the healthcare industry continues to evolve, Izotropic Corporation is positioned to play a significant role in enhancing breast cancer diagnostics.
AI Generated • Aug 5, 2026

Industry

Healthcare Equipment and Supplies

CEO

Robert Louis Thast

Headquarters

Surrey, BC V4A 2H9, CA

IZOZF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

48.20%

Return on Capital

N/A

Return on Assets

-368.33%

Earnings Yield

-16.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

68.98M

Volume

4.50K

Avg. Volume

15.62K

Financials (TTM)

Gross Profit

-CA$26.79K

Operating Income

-CA$2.49M

EBITDA

-CA$2.10M

Operating Cash Flow

-CA$900.05K

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$900.05K

Cash & ST Invst.

CA$364.66K

Total Debt

CA$3.14M

Izotropic Performance Analysis

Izotropic annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-04-30CAD 0N/A
20232023-04-30CAD 0N/A
20242024-04-30CAD 0N/A
20252025-04-30CAD 0N/A
Izotropic sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-04-30N/A
Q12025-07-31N/A
Q22025-10-31N/A
Q32026-01-31N/A
Izotropic annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-04-30CAD -0.12N/A
20232023-04-30CAD -0.09-31.0%
20242024-04-30CAD -0.02-74.7%
20252025-04-30CAD -0.0478.6%
Izotropic sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-04-30-101.2%
Q12025-07-3171.3%
Q22025-10-31-152.1%
Q32026-01-3166.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$7.65K

+17.0%

Gross Margin

0.00%

N/A

Market Cap

$11.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.37M

N/A

Employees

5

N/A

Net Income

-CA$262.52K

+46.1%

EBITDA

-CA$352.84K

+14.4%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$364.66K

+65.2%

Total Debt

CA$3.14M

+54.9%

Accounts Receivable

CA$5.46K

+11.0%

Inventory

CA$0.00

N/A

Long Term Debt

CA$68.03K

+1625.4%

Short Term Debt

CA$3.07M

+51.9%

Return on Assets

-3.68%

N/A

Return on Invested Capital

47.45%

N/A

Free Cash Flow

-CA$157.47K

+24.8%

Operating Cash Flow

-CA$157.47K

+24.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVCNFAvicanna Inc.
$0.09-7.00%
EMITFElbit Imaging Ltd.
$1.60+0.00%
MEDIFMediPharm Labs Corp.
$0.05+0.77%
RAPHRaphael Pharmaceutical Inc.
$1.40+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About IZOZF

What is the current price of Izotropic?

Izotropic is trading at $0.17 per share.

What is the 52-week range for Izotropic?

Over the past 52 weeks, Izotropic has traded between $0.12 and $0.37.

How much debt does Izotropic have?

As of the most recent reporting period, Izotropic reported total debt of CA$2.32M.

How much cash does Izotropic have on hand?

Izotropic reported CA$268.86K in cash and cash equivalents in its most recent financial results.

What is Izotropic’s dividend yield?

Izotropic does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.